Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other 1Head & Neck 1

Conditions

Neoplasms 2Pancreatic Neoplasms 1Mucositis 1Head and Neck Neoplasms 1

Interventions

Cisplatin 150Radiotherapy 121Cetuximab 96Docetaxel 60Fluorouracil 56Paclitaxel 45Radiotherapy, Intensity-Modulated 41Carboplatin 40pembrolizumab 34Surveys and Questionnaires 22Erlotinib Hydrochloride 19Nivolumab 18Immunohistochemistry 16Gefitinib 16Drug Therapy 16Gemcitabine 14Pemetrexed 13Gene Expression Profiling 13durvalumab 12Chemotherapy, Adjuvant 12Radiation 11Filgrastim 11Bevacizumab 11Surgical Procedures, Operative 10Polymerase Chain Reaction 10Amifostine 10Celecoxib 9Capecitabine 9Standard of Care 8Neoadjuvant Therapy 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Head and Neck Neoplasms × kang-lai-te × Clear all
NCT03101514 2021-06-23

Kanglaite Reduce the Toxicity of Radiotherapy of Head and Neck Cancer Phase II Study

First Affiliated Hospital of Harbin Medical University

Phase 2 Completed
53 enrolled 11 charts
Head & NeckOther

Head and Neck Neoplasms, Neoplasms, Mucositis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡